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Introduction: Data is scarce regarding adverse events (AE) of biological therapy used in the 
management of Crohn’s Disease (CD) among Brazilian patients. 
Objectives: To analyse AE prevalence and profile in patients with CD treated with Infliximab 
(IFX) or Adalimumab (ADA) and to verify whether there are differences between the two 
drugs. 
Method: Retrospective observational single-centre study of CD patients on biological therapy. 
Variables analysed: Demographic data, Montreal classification, biological agent adminis-
tered, treatment duration, presence and type of AE and the need for treatment interruption. 
Results: Forty-nine patients were analysed, 25 treated with ADA and 24 with IFX. The groups 
were homogeneous in relation to the variables studied. The average follow-up period for 
the group treated with ADA was 19.3 months and 21.8 months for the IFX group (p = 0.585). 
Overall, 40% (n = 10) of patients taking ADA had AE compared with 50% (n = 12) of IFX users 
(p = 0.571). There was a tendency towards higher incidence of cutaneous and infusion reac-
tions in the IFX group and higher incidence of infections in the ADA treated group, although 
without significant difference. 
Conclusions: No difference was found in the AE prevalence and profile between ADA and IFX 
CD patients in the population studied.
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Palavras-chave:
Doença de Crohn
Fator de necrose tumoral-alfa
Segurança
r e s u m o
Análise comparativa dos eventos adversos entre Infliximabe e 
Adalimumabe no tratamento da doença de Crohn: experiência  
em um centro brasileiro
Introdução: Há poucos dados sobre os eventos adversos (EA) da terapia biológica usada no 
tratamento da doença de Crohn (DC) entre os pacientes brasileiros.
Objetivos: Analisar a prevalência dos EA e o perfil dos pacientes com DC tratados com Infli-
ximabe (IFX) ou Adalimumabe (ADA) e verificar se há diferenças entre esses dois fármacos. 
Método: Estudo observacional e retrospectivo de pacientes com DC em terapia biológica, re-
alizado em centro único. As variáveis analisadas foram: dados demográficos, classificação 
de Montreal, agente biológico administrado, duração do tratamento, presença e tipo de EA 
e necessidade de interrupção do tratamento. 
Resultados: Quarenta e nove pacientes foram analisados, 25 tratados com ADA e 24 com 
IFX. Os grupos eram homogêneos em relação às variáveis estudadas. O período médio de 
acompanhamento foi de 19,3 meses para o grupo tratado com ADA e de 21,8 meses para o 
grupo tratado com IFX (p = 0,585). No total, 40% dos pacientes (n = 10) que receberam ADA 
tiveram AE, em comparação com 50% dos pacientes (n = 12) que receberam IFX (p = 0,571). 
Houve uma maior incidência de reação cutânea e à infusão no grupo IFX e de infecções no 
grupo ADA, embora sem diferença significativa.
Conclusão: Não houve diferença na prevalência de EA e no perfil dos pacientes com DC que 
receberam ADA e IFX.
Introduction
Inflammatory bowel diseases (IBD), Crohn’s disease (CD) and 
ulcerative colitis (UC) remain an important challenge for 
physicians and patients with regard to treatment and clinical 
follow-up. Recent therapeutic progress has been achieved in 
the management of IBD, whereby biological therapy is cur-
rently one of the most studied forms of treatment among 
these patients.1
CD is a chronic inflammatory condition of the gastroin-
testinal tract which is characterized by periods of remission 
and relapse, progressing over the years to complications 
such as stenosis, fistulas or abscesses.1 Its pathogenesis is 
not yet totally understood. Tumour necrosis factor-alpha 
(TNF-α) is an important cytokine involved in the develop-
ment of CD and it plays an important role in the genesis and 
sustainability of the inflammatory process in the inflamed 
areas.3,4,5 
Considering IBD physiopathology, whereby the pro-in-
flammatory factors are directly involved in the genesis of in-
flammation, therapeutic options have been developed aim-
ing the blockage of TNF-α in order to delay the progression of 
the disease and its complications.4,5
Two agents are available in Brazil to inhibit TNF-α in 
the treatment of CD. Infliximab (IFX) [Remicade®, Centocor, 
USA], a chimeric monoclonal antibody containing 25% of 
murine protein and administered intravenously, has been 
authorized for CD patients since the year 2000. It is the most 
studied drug regarding biological therapy in CD. Clinical tri-
als have demonstrated the efficacy in induction therapy and 
maintenance of remission of IFX in patients with moderate 
to severe disease, including those with fistulas.1,6,7,8 IFX has 
also been approved for children with CD and for the man-
agement of UC.6,8,9
Adalimumab (ADA) [Humira®; Abbott Laboratories, Abbott 
Park, USA] is a 100% human monoclonal antibody admin-
istered subcutaneously and its use has been authorized in 
Brazil since 2007. ADA is also indicated for induction and 
maintaining remission in moderate to severe refractory CD. 
Its action has also been proven in the event of IFX failure.2,3,10 
ADA is currently not approved for the management of chil-
dren with CD and it was recently approved for the manage-
ment of UC in the United States and Europe.
The efficacy of these two anti-TNF agents has been ex-
haustively documented in the literature by important ran-
domized pivotal studies.3,6 Remission rates following in-
duction with varying periods of maintenance are similar 
between the two drugs. Some authors consider these drugs 
to be similar in various aspects and question the theory of a 
TNF-α inhibitor class effect.11
Likewise, the safety profile and the adverse events (AE) of 
IFX and ADA appear to be similar. Both drugs have the poten-
tial to cause cutaneous reactions, opportunistic infections, 
abscesses, respiratory tract infections and rare conditions 
such as optic neuritis, multiple sclerosis and lupus-like reac-
tions.1,12 Some AE are characteristic of the drug application, 
such as reactions at the subcutaneous injection site (ADA) 
and infusion reactions of anaphylactic and immunological 
origin (IFX). AE can vary between simpler conditions, such as 
sinusitis and urinary infections, to more important effects, 
such as severe infections and sepsis leading to death.2,6,12
Due to the lack of solid studies of the efficacy and safe-
ty of anti-TNF-α agents in Brazilian patients with CD, more 
research is necessary in order to adequately elucidate the 
prevalence and profile of AE in this population in reference 
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
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centres. Therefore, real-life information found in everyday 
clinical practice in CD management can be applied to improve 
the knowledge in our field.
Objectives
The primary objectives of this study was both to analyse the 
prevalence and profile of AE in patients with CD treated with 
IFX or ADA, from a single centre cohort of one IBD reference 
centre from the Southern Region of Brazil, as well as to verify 
whether there are significant differences between the two 
drugs.
The secondary objectives were to analyse demographic 
data, follow-up period with the agents and the presence of 
treatment interruption due to AE.
Method
This study’s research project obtained prior approval from the 
Human Research Ethics Committee of the Pontifícia Universi-
dade Católica of Paraná (CEP – PUCPR) under reference num-
ber 0005345/11.
It was a retrospective, longitudinal and observational study 
with CD patients from a single IBD reference centre from the 
South of Brazil. All patients from a CD cohort that were treat-
ed with any biological agent (IFX or ADA) at any stage of their 
management were included in the study, over 18 years old, in 
the period between January 2002 and December 2011. Patients 
with UC, indeterminate IBD and those who lost follow-up af-
ter the induction of clinical remission were excluded.
Data were collected by electronic chart review and docu-
mented in accordance with a previously established specific 
protocol. Once the data had been compiled it was tabulated to 
enable subsequent analysis and evaluation.
The following variables were analysed: demographic data 
(gender and mean age), disease presentation and location ac-
cording to the Montreal classification, concomitant use of im-
munosuppressive drugs, the biological agent used, treatment 
duration, presence of AE, type of event observed and the need 
for treatment interruption.
The patients were allocated into two groups according to 
the biological agent, either IFX or ADA. A comparison was 
made of the data on the prevalence and type of AE in the two 
groups. The study’s hypothesis was that there would be no 
difference between the AE prevalence and profile observed in 
the two groups.
The AE of pain at the subcutaneous injection site (ADA) or 
venous puncture in the case of IFX administration were ex-
cluded from the analysis, as pain is a subjective characteristic 
and the vast majority of patients report this consequence of 
drug administration. In the IFX group, the occurrence of in-
fusion reaction was considered to be an adverse effect, this 
being a characteristic unique to this drug owing to its phar-
macological features.
Sample size calculation was not performed in this study. 
Rather, convenience sampling was used according to the real 
number of patients in the cohort previously mentioned. The 
results obtained through the study were described in terms of 
averages, minimum values, maximum values and standard 
deviations (quantitative variables) or in terms of frequencies 
and percentages (qualitative variables). Fisher’s exact test or 
the Chi-square test were used in the evaluation of the asso-
ciation between treatment and qualitative variables. The Stu-
dent’s t test for independent samples or the Mann-Whitney 
non-parametric test were used when comparing treatment 
in relation to quantitative variables. P values < 0.05 indicated 
statistical significance. The data were analysed using the Sta-
tistica v.8.0 software. 
Results
A total of 49 patients with CD were included in the analysis, 
25 of whom were treated with ADA and the remaining 24 were 
treated with IFX. There was no statistical difference between 
the groups regarding mean age and gender. Similarly, when 
analysing the CD phenotype characteristics in relation to the 
Montreal classification (age of diagnosis, disease location and 
the phenotype of its presentation) once again there was no 
statistical difference between the groups. This absence of dif-
ference between the groups from the statistical point of view 
was also observed in relation to the following variables: pres-
ence of perianal disease, concomitant  immunosuppressive 
drugs and follow-up period. The groups were therefore con-
sidered to be homogeneous and comparable for the purposes 
of this analysis. This data can be found in detail in Table 1.
Regarding the incidence of AE observed in the groups, 
these occurred in 40% of patients with CD treated with ADA 
(n = 10 of the 25 patients) and in 50% of those treated with 
IFX (n = 12 of the 24 patients) (p = 0.571). In terms of the ab-
solute number of events observed, 14 AE were observed in 10 
patients in the group treated with ADA, and 12 events in 12 
patients treated with IFX (p = 0.911). This means that some 
patients had more than one AE during treatment. Based on 
these results, no significant difference was found in the rate 
of adverse events in the two groups (Table 2).
Table 1 – Baseline characteristics of the patients. There 
was no statistical difference between the groups, 
considered to be homogeneous.
ADA (n = 25) IFX (n = 24) p value
Mean age (years) 37.5 (18-80)  
SD = 14.1
41.3 (19-70)  
SD = 14.6
0.352
Male gender 13 (52) 14 (58.33) 0.776
Female gender 12 (48) 10 (41.67)
A1 6 (24) 5 (20.83) 0.138
A2 14 (56) 8 (33.33)
A3 5 (20) 11 (45.83)
L1 4 (16) 3 (12.5) 0.897
L2 11 (44) 10 (41.67)
L3 10 (40) 11 (45.83)
L4 0 (0) 0 (0) —
B1 4 (16) 7 (29.17) 0.269
B2 4 (16) 1 (4.17)
B3 17 (68) 16 (66.67)
Perianal disease 19 (76) 17 (70.83) 0.754
Concomitant 
immunosuppressants
22 (88) 21 (87.5) 1.000
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The profile of the AE is demonstrated in Table 3. A tenden-
cy of greater occurrence of cutaneous and infusion reactions 
was observed in the IFX group. A greater tendency of infec-
tious AE, such as sinusitis, herpes simplex and herpes zoster 
was observed in the ADA group (Table 3). Nevertheless, there 
was no statistical difference in relation to these data.
Figs. 1, 2, 3 and 4 show some of the AE found in the patients 
included in the study, with detailed subtitles.
In this study, some cases of treatment interruption due to 
AE were observed. In the IFX group, 8 of the 12 patients with 
AE had to interrupt their biological treatment. In the group 
of ADA, 4 of the 10 patients had AE that lead to treatment 
interruption. There was no statistical difference between the 
groups in relation to this variable (Fig. 5). 
Discussion
The efficacy of anti-TNF agents in the treatment of CD is well-
known and clearly demonstrated in the literature. Various 
randomized trials have been performed showing the benefits 
of this treatment in the remission of the disease.3,6 Neverthe-
less, there is significant concern regarding the safety of the 
administration of biological agents to treat CD patients. The 
safety profile of these drugs has been described in various 
studies which have demonstrated the occurrence of common 
events such as headache, infections and infusion reactions, 
Table 2 – Prevalence of AE in the two groups of patients. 
Absence of statistical difference in relation to frequency 
(p = 0.571).
Adverse 
events: n (%)
ADA (n = 25) IFX (n = 24) Total p value
No 15 (60) 12 (50) 27 p = 0.571
Yes 10 (40) 12 (50) 22
Total 25 24 49
Table 3 – Profile of the AE found in the two groups of 
patients. Individually, for each type of event, there was 
no significant difference between the groups.
Adverse effect (n/%) ADA (n = 25) IFX (n = 24) p value
Cutaneous reactions 2 (8) 4 (16.7) 0.367
Sinusitis 3 (12.5) 1 (4.17) 0.609
Arthralgia 2 (8) 1 (4.17) 1.000
Severe infusion 
reaction
0 (0) 3 (12.5) 0.110
Alopecia 2 (8) 0 (0) 0.490
Slight infusion 
reactions 
0 (0) 2 (8.33) 0.235
Headache 1 (4) 0 (0) 1.000
Herpes simplex 1 (4) 0 (0) 1.000
Herpes zoster 1(4) 0 (0) 1.000
Perianal HPV 0 (0) 1 (4.17) 0.490
Ungueal inflammation 1 (4) 0 (0) 1.000
Leukocytoclastic 
vasculitis
1(4) 0 (0) 1.000
Mean follow-up period 
(months)
19.3 (3-39) 21.8 (2-81) 0.585
Fig. 1 – Leukocytoclastic vasculitis after 3 years of ADA 
treatment.
Fig. 3 – Facial cutaneous reaction an IFX-treated patient.
Fig. 2 – Herpes zoster infection during ADA treatment in a 
patient with severe CD and short bowel syndrome.
as well as other situations, such as opportunistic infections, 
lymphomas, demyelinating disease and lupus-like reactions.2
The two groups of patients included in this study were 
considered to be homogeneous. The median age of patients 
receiving IFX was 41.3 years, this being similar to that found 
in the literature in two studies with large patient samples, in 
which the median ages were 35 and 37 years.8,13 With regard 
to the demographic profile of the patients treated with ADA, 
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the median age found in this study, 37.5 years, is also similar to 
that found in pivotal studies with the same drug (37.1 and 38.3 
years).2,3 In both groups of our study, there was also predomi-
nance of the fistulizing form of CD, which can be explained by 
the fact that fistulas are one of the main indications for bio-
logical therapy, in addition to the bias caused by the reference 
centre in question being located in a colorectal surgery unit. 
The duration of follow-up, which is an important variable in 
retrospective comparisons between treatments, was also simi-
lar, with no significant statistical difference, and was greater 
than 18 months in both groups.
The administration of concomitant immunosuppressive 
drugs with anti-TNF agents was expressive in this sample. Ap-
proximately 88% of patients under ADA treatment and 87.5% 
of those receiving IFX were also exposed to some type of im-
munomodulators during their treatment. Controversy exists 
regarding this issue as there is scarce evidence to support the 
combined use of ADA and immunosuppressive drugs in ran-
domized studies. In the literature, the concomitant adminis-
tration of these drugs in the treatment of inflammatory bowel 
diseases is also very frequent. In a randomized study published 
in 2002, 51% of patients used some type of corticosteroid, 50% 
were on 5-aminosalicylates, 25% were exposed to 6-mercap-
topurine or azathioprine and 4% used methotrexate, concur-
rently with IFX. This data demonstrates that in the past the 
concept of combining biologics with immunosuppressive 
agents had not been consolidated, judging by the low number 
of patients taking the two drugs concurrently. The numbers 
in this study are higher with regard to the use of combination 
therapy (greater than 85%). This can be explained by the more 
recent global tendency of using this treatment strategy, data 
that were consolidated with the publication of the SONIC study 
in 2010.6,13 Whether this combination may increase the rate of 
side effects has yet to be elucidated.
The occurrence of AE in patients under ADA treatment is 
documented in the literature in the form of opportunistic in-
fections, such as oral candidiasis, rare lupus-like reactions, 
demyelinating disorders such as multiple sclerosis and optic 
neuritis, and congestive heart failure induced by this drug. Ab-
scesses are the most serious form of infection, followed by gas-
trointestinal and pulmonary infections. Nevertheless, herpes 
zoster infection is also reported.2
The incidence of malignancies, such as lymphomas, despite 
not being clearly established, may be present in some rare cas-
es. It is not clear whether the occurrence of neoplasms is asso-
ciated with the biological agent per se or with the concomitant 
use of immunosuppressive agents. There were no neoplasms 
in the cases described in our series.
In the group using ADA in this sample, although the num-
ber of patients was reduced, greater occurrence of infectious 
adverse events was observed, whereby 12.5% of patients had 
sinusitis and 8% had herpes simplex and herpes zoster infec-
tions (Table 3). The patients included in the CHARM study3 had 
adverse effects in 59.4% of the cases (507/854) during the main-
tenance period, compared with 40% (10/25) in our group. It 
must be emphasized that in the above mentioned randomized 
study, pain at the subcutaneous injection site was included as 
an adverse effect and this may explain the higher incidence of 
events considered to be adverse.3
With regard to IFX, some adverse effects can be explained 
by the formation of antibodies against the drug (anti-IFX anti-
bodies), leading to acute or delayed infusion reactions. Respira-
tory tract infections of variable severity can also occur with the 
administration of this drug. In some cases, more severe infec-
tious conditions, such as fatal sepsis, pneumonia, viral infec-
tions and abdominal abscesses are described. The use of IFX by 
patients with congestive heart failure is accompanied by a risk 
of worsened functional classification. Although other manifes-
tations such as optic neuritis, multiple sclerosis and lupus-like 
reactions are reported, they are rare.1 The presence of anti-IFX 
antibodies or IFX serum levels were not assessed in this study.
Overall, 50% (12/24) of the patients in this study under IFX 
therapy presented some type of AE: 16.7% had some type of cu-
taneous lesion, 12.5% had a severe infusion reaction and 8.3% 
had slight infusion reaction. Other studies in the literature 
have already demonstrated the significant incidence of infu-
sion reactions, as occurred in this study. In the ACCENT II trial,8 
16% of patients had infusion reactions when submitted to IFX 
therapy, this percentage being close to that found in the case 
series in our study. 
Tuberculosis reactivation during treatment with ADA or IFX 
is described in the literature. None of the patients in this series 
had this adverse effect. All of them began biological therapy 
after rigorous PPD testing and chest x-rays, as well as sequenc-
Fig. 4 – Hand cutaneous reaction during IFX treatment.
Fig. 5 – Results regarding treatment interruption rates 
owing to AE. No statistical difference between the groups. 
84%
100%
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ing tests when necessary. It is known that even when taking 
these precautions, cases of latent tuberculosis can manifest 
themselves, although this did not occur with the patients in 
this study. No deaths occurred in this case series.
The ADA and IFX efficacy and safety profiles appear to be 
similar in relation to experiences found in the literature. It 
must be emphasized that comparative head to head prospec-
tive studies with the two drugs have not been published, thus 
partially limiting this affirmation. As such a question arises as 
to the possible existence of a class effect between TNF-alpha 
inhibitors, not just in terms of safety but also in relation to ef-
ficacy.11 This question is equally controversial in the interna-
tional literature. The results of this study present a tendency 
towards similarity in the adverse events found with both drugs.
We are aware that this study has significant limitations. In 
addition to its methodological design, such as the small num-
ber of patients in the sample and being a retrospective study 
capturing data by reviewing patients’ medical records, there 
are also the limitations of the relatively short average period 
of follow-up of the patients analysed (less than 2 years for 
both groups). Another limitation that can be taken into con-
sideration relates to the period analysed by the study which 
includes patients treated for more than 9 years. Treatment us-
ing biological agents has evolved in recent years and the form 
of treatment used at the beginning of the millennium is a little 
different to the form currently used. This may have caused bias 
in the results, mainly due to the more recent tendency of using 
combination therapy.
Conclusions
Secondary adverse effects to anti-TNF therapy were found 
in 40% of the patients treated with ADA and in 50% of those 
treated with IFX, with no significant statistical difference. With 
regard to the profile of the events found, there was a tendency 
of greater incidence of cutaneous and infusion reactions in the 
group treated with IFX and a tendency of greater incidence of 
infections in the group treated with ADA. The patients’ demo-
graphic data were similar to those described in the literature. 
This is one of the first Brazilian experiences published contain-
ing data related to the safety profile in patients with CD treated 
with biological therapy.
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